Plain-English translation of NCT06623630 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a combination of low-dose radiation and chemotherapy can safely prepare your body for (Cilta-cel), a newer type of blood cell therapy for multiple myeloma. Most studies of this medication have excluded patients with kidney problems, even though kidney disease is common in myeloma. This study focuses specifically on whether this medication works well and safely for people whose kidneys aren't functioning normally.
Many myeloma patients have impaired kidney function, but they were left out of the main clinical trials that tested this treatment. This study aims to fill that gap and make sure that people with kidney problems can safely benefit from this medication too.
You likely qualify if…
You likely don't qualify if…
Your blood cells will be collected and specially modified in the laboratory to create your personalized treatment. You will then receive chemotherapy by IV for a few days, followed by low-dose radiation the day before your modified cells are infused back into you. The trial will track your response to treatment and monitor you for safety, though the full duration and number of visits are not specified in this summary.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States